Millennium Management
BCAX

Millennium Management’s Bicara Therapeutics BCAX Stock Holding History

Millennium Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.12M Sell
156,702
-277,997
-64% -$4.79M ﹤0.01% 3434
2025
Q4 		$7.32M Sell
434,699
-580,193
-57% -$9.91M ﹤0.01% 2595
2025
Q3 		$16M Buy
1,014,892
+273,873
+37% +$3.07M 0.01% 1917
2025
Q2 		$6.88M Buy
741,019
+715,371
+2,789% +$8.53M ﹤0.01% 2642
2025
Q1 		$334K Sell
25,648
-359,758
-93% -$4.78M ﹤0.01% 5040
2024
Q4 		$6.71M Buy
385,406
+85,847
+29% +$1.79M ﹤0.01% 2551
2024
Q3 		$7.63M Buy
+299,559
New +$7.64M ﹤0.01% 2445

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Millennium Management's BCAX Position: Q1 2026 in Review

Millennium Management reduced its Bicara Therapeutics (BCAX) stake by 64% in Q1 2026, selling an estimated $4.79M and leaving 156,702 shares worth $3.12M. The position accounts for ﹤0.01% of the portfolio, ranked #3434.

Millennium Management first reported a position in BCAX in Q3 2024 and has held it in 7 quarters since. The position peaked at $16M in Q3 2025. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Millennium Management held 156,702 shares of Bicara Therapeutics worth $3.12M as of Q1 2026.
  • Millennium Management sold 277,997 Bicara Therapeutics shares in Q1 2026, an estimated $4.79M.
  • Bicara Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3434 holding.
  • Millennium Management first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Millennium Management's Bicara Therapeutics position peaked at $16M in Q3 2025.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.